Skip to Content
Merck
CN

A6681

2-Acetamido-1-N-(β-L-aspartyl)-2-deoxy-β-D-glucopyranosylamine

≥98%

Synonym(s):

β-D-GlcNAc-(1→N)-Asn, 2-Acetamido-1-β-(L-aspartamido)-1,2-dideoxy-D-glucose, L-Asparagine, N-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C12H21N3O8
CAS Number:
Molecular Weight:
335.31
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352201
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C12H21N3O8/c1-4(17)14-8-10(20)9(19)6(3-16)23-11(8)15-7(18)2-5(13)12(21)22/h5-6,8-11,16,19-20H,2-3,13H2,1H3,(H,14,17)(H,15,18)(H,21,22)

SMILES string

CC(=O)NC1C(O)C(O)C(CO)OC1NC(=O)CC(N)C(O)=O

InChI key

YTTRPBWEMMPYSW-UHFFFAOYSA-N

assay

≥98%

form

powder

optical activity

[α]/D 22 to 26 °, c = 1% (w/v) in water

technique(s)

thin layer chromatography (TLC): suitable

storage temp.

−20°C

Application

n-acetylglucosaminylasparagine [2-Acetamido-1-N-(β-L-aspartyl)-2-deoxy-β-D-glucopyranosylamine] may be useful in studies on Aspartylglycosaminuria.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

U Dunder et al.
FEBS letters, 499(1-2), 77-81 (2001-06-22)
Aspartylglycosaminuria (AGU), a severe lysosomal storage disease, is caused by the deficiency of the lysosomal enzyme, glycosylasparaginase (GA), and accumulation of aspartylglucosamine (GlcNAc-Asn) in tissues. Here we show that human leukocyte glycosylasparaginase can correct the metabolic defect in Epstein-Barr virus
M Arvio et al.
Acta neurologica Scandinavica, 112(5), 335-337 (2005-10-13)
To show that the head may shrink in adult patients with aspartylglucosaminuria (AGU), a neurodegenerative disease. The head circumference (HC) of 40 adult patients (age at baseline 15 to 47) was measured twice with an interval of 10 years. Of
Niki Lindblom et al.
Journal of inherited metabolic disease, 29(5), 637-646 (2006-09-01)
Sleep disturbances are common in many progressive metabolic encephalopathies. The possible presence of disturbed sleep-wake behaviour in the lysosomal storage disorder aspartylglucosaminuria, has not been previously studied, however. The sleep-wake behaviour of 81 patients with aspartylglucosaminuria (AGU, age 3-55 years
J M Risley et al.
Journal of enzyme inhibition, 16(3), 269-274 (2001-11-08)
Glycosylasparaginase catalyzes the hydrolysis of the N-glycosylic bond between asparagine and N-acetylglucosamine in the catabolism of N-linked glycoproteins. Previously only three competitive inhibitors, one noncompetitive inhibitor, and one irreversible inhibitor of glycosylasparaginase activity had been reported. Using human glycosylasparaginase from
Ulla Dunder et al.
Journal of inherited metabolic disease, 33(5), 611-617 (2010-07-08)
Aspartylglycosaminuria (AGU) is a lysosomal storage disease caused by deficient activity of glycosylasparaginase (AGA), and characterized by motor and mental retardation. Enzyme replacement therapy (ERT) in adult AGU mice with AGA removes the accumulating substance aspartylglucosamine from and reverses pathology

Articles

N-linked glycosylation, modification, and degradation

N-连接聚糖、修饰和降解

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service